ABOUT GENSCO® PHARMA
Gensco® Pharma is a specialty pharmaceutical company focusing on research, development and marketing of transdermal prescription products. As an innovator of pharmaceutical products, Gensco® Pharma currently manufactures non-narcotic transdermal analgesic gels utilizing our patented drug delivery solutions. Gensco® Pharma’s airless, closed-system, metered dose technology, MDose™, dispenses the exact amount of medication per application, yielding maximized results and minimized side effects. As a healthcare partner, Gensco® is in continual pursuit of novel and effective therapies designed to improve health.
Gensco® Pharma: healthcare visionaries, boundless…
MISSION STATEMENT
Gensco® Pharma is committed to Better Science for Health.
Our resources are focused on innovative research, the development of superior quality medications and unique delivery systems. We are an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.
WORKING WITH GENSCO®
Gensco® works with nationally recognized suppliers. We are a rapidly growing branded pharmaceutical manufacturer that extends resources including education and training along with customized marketing programs to help grow our distributor partner business. Internally, Gensco® team members provide an array of support services to enable the supply chain seamless delivery and to ensure desired market penetration for our partners. 
GENSCO® TRENDING
Looking To The Future
RizaFilm migraine treatment launching Q5
Launching in Q4 2025, RizaFilm® delivers fast, water-free migraine relief through novel oral dissolvable film (ODF) technology—offering unmatched convenience, portability, and speed in a tablet-dominated market.
- Gensco Pharma® Acquires Global Rights and IP for RizaFilm® and RizaPort® May 13, 2025 Featured, Industry, Press Release, Product Update - Gensco Pharma acquires global rights to RizaFilm® and RizaPort®, with a U.S. migraine treatment launch… more...
- Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States September 26, 2023 Featured, Industry, Press Release, Product Update - Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch… more...
- Skin Tears Treatment Market to Observe Strong Development by 2018-2026 April 15, 2019 Articles, Featured, Industry - [To download a printable version of this article, click here] MARKET RESEARCH April 12, 2019… more...
- Gensco® Pharma Partners with IntelGenx to Launch and Commercialize RIZAFILM® (U.S. market name for RIZAPORT® — Rizatriptin Oral Film) in the United States December 12, 2018 Featured, Industry, Press Release, Product Update - Miami, Florida, December 12, 2018 – Gensco® Pharma, a leading specialty pharmaceutical manufacturer specializing in… more...